Creative Biolabs is a well-recognized expert in the field of antibody generation and production. Especially, we have launched a series of in vitro diagnostic (IVD) antibody/immunoassay development services for different infections and diseases. Here, we introduce our antibody/immunoassay development services targeting different biomarkers of asthma.
Asthma is a common long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurrent symptoms, reversible airflow obstruction and bronchospasm. Asthma has been confirmed as early as ancient Egypt. It usually starts in childhood. Since the 1960s, the incidence of asthma has increased significantly. Common signs and symptoms of asthma include wheezing, coughing, chest tightness, shortness of breath, etc. Symptoms can be prevented by avoiding triggering factors (such as allergens and irritants) and using inhaled corticosteroids. If asthma symptoms are not controlled, long-acting beta-agonists (LABA) or anti-leukotriene drugs may be used in addition to inhaled corticosteroids. Treatments for rapidly worsening symptoms are usually an inhaled short-acting beta-2 agonists such as salbutamol and oral corticosteroids. In severe cases, intravenous injections of corticosteroids, magnesium sulfate, and hospitalization may be required.
Making improvements in diagnosis and monitoring of asthma is important to identify susceptible individuals and to start early treatment. Traditional diagnostic techniques mainly rely on clinical features (symptoms), spirometry examinations, or peak flow rate measurements. However, the clinical features of asthma are non-specific and pulmonary function tests are often insensitive. Non-invasive biomarkers that can be measured in easily obtainable samples, such as the exhaled gases, sputum, blood, and urine, have been discovered and validated to be useful in clinical practice. Moreover, novel biomarkers that may be associated with asthma are continuously emerging. The combination of these diagnostic tools improves diagnostic accuracy and management of asthma.
Non-invasive IVD tests that apply the immunoassay technology have been developed targeting some of the asthma biomarkers. They measure single analyte or multiple analytes in blood, urine, or other samples, to aid in screening and diagnosis, severity assessment, therapy guiding, disease control, and prognosis of asthma. As more and more technology platforms and new biomarkers are emerging, new diagnostic kits are being developed as well, to provide a quicker, more specific and more accurate diagnosis of asthma. Most of these IVD immunoassays are based on the use of antibodies/antigens to detect the analytes.
The development of diagnostic immunoassays is a time-consuming, resource-intensive effort. Particularly, the use of high-quality reagents, antibodies or antigens, is of great importance to achieve higher sensitivity and accuracy. Creative Biolabs has built a versatile IVD antibody development platform to provide custom IVD antibody development services for a broad range of disease biomarkers. Besides, we also help our clients with contract research in immunoassay development, providing support in assay design, critical raw material sourcing, component formulation, assay optimization & validation, and kit production. Our expertise lies in a broad array of immunoassay platforms, including ELISA (enzyme-linked immune-sorbent assay), LFIA (lateral flow immunoassay), CLIA (chemiluminescent immunoassay), IHC (immunohistochemistry), etc. For more information please click the links below:
For asthma, we focus on various biomarkers including but not limited to:
Please feel free to contact us to discuss your project requirements.
References
For Research Use Only.
